|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3535298 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17808224.4 |
| Date of filing the European patent application | 2017-11-01 | |
| (97) | Date of publication of the European application | 2019-09-11 |
| (45) | Date of publication and mention of the grant of the patent | 2021-09-08 |
| (46) | Date of publication of the claims translation | 2021-12-27 |
| (86) | Number | PCT/US2017/059481 |
| Date | 2017-11-01 |
| (87) | Number | WO 2018/085358 |
| Date | 2018-05-11 |
| (30) | Number | Date | Country code |
| 201662416602 P | 2016-11-02 | US |
| (72) |
MABRY, George Robert, III , US
SAZINSKY, Stephen , US
|
| (73) |
Jounce Therapeutics, Inc. ,
780 Memorial Drive, Cambridge, MA 02139,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Antikūnai prieš PD-1 ir jų panaudojimas |
| ANTIBODIES TO PD-1 AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2023-10-23 | 7 | 162.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-11-01 |